Publicações

Four-Year Survival in Patients (Pts) Undergoing Liver Surgery After Neoadjuvant Triplet Hepatic Artery Infusion (Hai) and Intravenous Cetuximab (Iv-Cet) for Previously Treated and Unresectable Liver Metastases from Kras Wt Colorectal Cancer (Lm-Crc) (European Trial Optiliv, Nct00852228).

AuthID
P-00P-9YX

Author(s)

Levi, F

Ducreux, M

Smith, DM

Hebbar, M

Lepere, C

Focan, CNJ

Guimbaud, R

Innominato, PF

Carvalho, C

Tumolo, S

Truant, S

Castaing, D

Karaboue, A

Boige, V

Bouchahda, M

Rougier, P

Adam, R

Group Author(s)

ARTBC Int

Tipo de Documento

Abstract

Year published

2014

Publicado

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 32, Número: 15

Conference

50Th Annual Meeting of the American-Society-Of-Clinical-Oncology, Date: MAY 30-JUN 03, 2014, Location: Chicago, IL, Patrocinadores: Amer Soc Clin Oncol

Indexing

Wos^®

Metadata
Fontes

Publication Identifiers

Wos: WOS:000358613203105

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Four-Year Survival in Patients (Pts) Undergoing Liver Surgery After Neoadjuvant Triplet Hepatic Artery Infusion (Hai) and Intravenous Cetuximab (Iv-Cet) for Previously Treated and Unresectable Liver Metastases from Kras Wt Colorectal Cancer (Lm-Crc) (European Trial Optiliv, Nct00852228).

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Four-Year Survival in Patients (Pts) Undergoing Liver Surgery After Neoadjuvant Triplet Hepatic Artery Infusion (Hai) and Intravenous Cetuximab (Iv-Cet) for Previously Treated and Unresectable Liver Metastases from Kras Wt Colorectal Cancer (Lm-Crc) (European Trial Optiliv, Nct00852228).

Links Úteis

Ajuda